Correlation Between Vaxcyte and Nuvectis Pharma
Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Nuvectis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Nuvectis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxcyte and Nuvectis Pharma, you can compare the effects of market volatilities on Vaxcyte and Nuvectis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Nuvectis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Nuvectis Pharma.
Diversification Opportunities for Vaxcyte and Nuvectis Pharma
0.16 | Correlation Coefficient |
Average diversification
The 3 months correlation between Vaxcyte and Nuvectis is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Nuvectis Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvectis Pharma and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Nuvectis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvectis Pharma has no effect on the direction of Vaxcyte i.e., Vaxcyte and Nuvectis Pharma go up and down completely randomly.
Pair Corralation between Vaxcyte and Nuvectis Pharma
Given the investment horizon of 90 days Vaxcyte is expected to generate 0.19 times more return on investment than Nuvectis Pharma. However, Vaxcyte is 5.22 times less risky than Nuvectis Pharma. It trades about -0.2 of its potential returns per unit of risk. Nuvectis Pharma is currently generating about -0.05 per unit of risk. If you would invest 10,611 in Vaxcyte on August 31, 2024 and sell it today you would lose (1,213) from holding Vaxcyte or give up 11.43% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Vaxcyte vs. Nuvectis Pharma
Performance |
| Timeline |
| Vaxcyte |
| Nuvectis Pharma |
Vaxcyte and Nuvectis Pharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Vaxcyte and Nuvectis Pharma
The main advantage of trading using opposite Vaxcyte and Nuvectis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Nuvectis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvectis Pharma will offset losses from the drop in Nuvectis Pharma's long position.| Vaxcyte vs. Larimar Therapeutics | Vaxcyte vs. Syndax Pharmaceuticals | Vaxcyte vs. Merus BV | Vaxcyte vs. Sutro Biopharma |
| Nuvectis Pharma vs. Replimune Group | Nuvectis Pharma vs. Lyra Therapeutics | Nuvectis Pharma vs. Kronos Bio | Nuvectis Pharma vs. Gossamer Bio |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Complementary Tools
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| CEOs Directory Screen CEOs from public companies around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |